DOAC is named as an intervention in 6 current clinical trials in our Germany, Spain, Italy, France, South Korea, Canada, Belgium, Switzerland, UK, USA, China, Brazil, Japan, Israel, Australia, Netherlands and Poland registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Insel Gruppe AG, University Hospital Bern (2). The most-studied condition is Carcinoma, Non-small-Cell Lung.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Carcinoma, Non-small-Cell Lung | 1 |
| Bleeding Post Cardiac Surgery | 1 |
| Indication for Anticoagulation | 1 |
| Percutaneous Coronary Intervention (PCI) | 1 |
| Atrial Fibrillation (AF) | 1 |
| Oral Anticoagulation | 1 |
| P2Y12 Inhibitor | 1 |
| Ischemic Stroke | 1 |
| Atrial Fibrillation | 1 |
| Hip Fracture Surgery | 1 |
| Cardiovascular Prevention | 1 |
| Venous Thromboembolism (VTE) | 1 |
| Myocardial Infarction (MI) | 1 |
| ST-Segment Elevation Myocardial Infarction(STEMI) | 1 |
| NSTEMI - Non-ST-Segment Elevation Myocardial Infarction | 1 |
| AF - Atrial Fibrillation | 1 |
| Lead sponsor | Trials |
|---|---|
| Insel Gruppe AG, University Hospital Bern | 2 |
| Janssen Research & Development, LLC | 1 |
| Population Health Research Institute | 1 |
| McMaster University | 1 |
| Chonnam National University Hospital | 1 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our Germany, Spain, Italy, France, South Korea, Canada, Belgium, Switzerland, UK, USA, China, Brazil, Japan, Israel, Australia, Netherlands and Poland registers name DOAC as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of the 6 trials are recruiting: 4 with sites in Germany, 3 with sites in Spain, 2 with sites in Italy, 2 with sites in France, 2 with sites in South Korea, 1 with sites in Canada, 2 with sites in Belgium, 2 with sites in Switzerland, 1 with sites in UK, 1 with sites in USA, 1 with sites in China, 1 with sites in Brazil, 1 with sites in Japan, 1 with sites in Israel, 1 with sites in Australia, 1 with sites in Netherlands and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Insel Gruppe AG, University Hospital Bern (2), Janssen Research & Development, LLC (1), Population Health Research Institute (1) and McMaster University (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how DOAC works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how DOAC works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists DOAC (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.